[Skip to Content]
[Skip to Content Landing]
Views 2,657
Citations 0
Editorial
February 17, 2020

Overuse of Broad-Spectrum Antibiotics for Pneumonia

Author Affiliations
  • 1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts
  • 2Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA Intern Med. Published online February 17, 2020. doi:10.1001/jamainternmed.2019.7251

The prevailing practice in many hospitals is to give immediate, often broad-spectrum, antibiotics to all hospitalized patients with possible infections. Two interlinked factors drive this practice: (1) clinicians fear that any delay in appropriate antibiotics may increase patients’ risk for worse outcomes including death, and (2) it is uncomfortable to withhold antibiotics from a patient who may have an infection, even if the likelihood of infection is low; doing something feels more responsive, responsible, and patient-centric than doing nothing. The net result, however, is widespread use of antibiotics, much of which is unnecessary. Overprescribing is particularly pronounced in patients with pneumonia. Study after study has documented high rates of pneumonia overdiagnosis, suggesting a rush to treat despite equivocal evidence of disease. Up to half of hospitalized patients treated for pneumonia may not actually have pneumonia.1,2

Adding insult to injury, hospitalized patients with suspected pneumonia are often treated with broad-spectrum antibiotics, a trend catalyzed by the 2005 American Thoracic Society and Infectious Diseases Society of America pneumonia treatment guidelines,3 which helped popularize the concept of health care-associated pneumonia. The guidelines recommended treating all patients with any recent contact with the medical system for potentially drug-resistant pathogens. The effect of this recommendation has been striking. Investigators from the Veterans Health Administration, for example, documented an increase in vancomycin prescribing from 16% of pneumonia hospitalizations in 2006 to 31% in 2010 and a parallel increase in piperacillin-tazobactam prescribing from 16% in 2006 to 27% in 2010.4 In practice, however, only 2% of patients with pneumonia had positive blood or sputum cultures for methicillin-resistant Staphylococcus aureus (MRSA) and 2% had positive cultures for Pseudomonas aeruginosa. Rates of MRSA have been steadily declining during the past 15 years, so the prevalence of MRSA pneumonia is likely even lower now.5

An emerging set of studies has added another layer of complexity to this story by suggesting that overtreatment with antibiotics in general and overuse of broad-spectrum agents in particular may not only be unnecessary but may in fact be deadly. The investigation by Jones and colleagues6 in this issue of JAMA Internal Medicine is the latest study to make this assertion.

Jones and colleagues6 retrospectively evaluated 88 605 hospitalizations for community-onset pneumonia in Veterans Affairs hospitals. More than one-third of patients (38%) were empirically treated for MRSA using vancomycin or linezolid. The investigators compared mortality rates among patients who received empirical anti-MRSA therapy vs those who did not, adjusting for possible differences between the 2 groups using state-of-the-art epidemiologic methods and detailed clinical data. Remarkably, Jones and colleagues6 found that patients treated with empirical anti-MRSA agents were about 36% more likely to die compared with patients treated with standard first-line agents for community-acquired pneumonia (typically a quinolone or the combination of a β-lactam plus a macrolide). This finding was consistent in subgroup analyses restricted to patients in the intensive care unit, patients with risk factors for MRSA infection, and patients with positive nasal polymerase chain reaction test results for MRSA. The only group for whom there was no clear signal of harm was the subset with positive clinical cultures for MRSA (2% of the study population). Jones and colleagues6 did elicit some potential mechanisms of harm: empirical vancomycin was associated with higher rates of acute kidney injury, Clostridium difficile infection, and hospital-acquired vancomycin-resistant Enterococcus or gram-negative bacteremia or bacteriuria.

The findings from this study need to be interpreted with caution. Patients treated with anti-MRSA regimens were sicker than those treated with standard regimens. And while the investigators applied state-of-the-art methods to try to control for confounding by indication, it is possible that there was residual confounding. Indeed, it is difficult to reconcile the investigators’ proposition that a few days of treatment with vancomycin (the anti-MRSA agent used 98% of the time) may increase mortality rates by almost 40% with either clinical intuition or randomized clinical trials that have compared vancomycin with other agents.7,8

Notwithstanding the uncertainties in this analysis, the finding that more aggressive antibiotic strategies may be associated with higher mortality rates compared with more conservative approaches has now been reported multiple times.9-11 Webb and colleagues,9 for example, reported that broad-spectrum antibiotics were associated with a 4-fold higher odds of death among 1995 adults treated for pneumonia in 4 Utah emergency departments. Likewise, Kett and colleagues11 reported that broad-spectrum regimens were associated with a 2-fold increase in mortality among 303 patients with health care-associated pneumonia and risk factors for multidrug-resistant pathogens.

Conversely, a growing number of studies suggest that deferring antibiotics until cultures return may not only be safe but may even be associated with lower mortality rates. Hranjec and colleagues,12 for example, compared outcomes in a surgical intensive care unit during a baseline year in which antibiotics were given immediately whenever infection was suspected vs the following year in which antibiotics were given only after objective confirmation of infection (patients requiring vasopressors could be treated immediately). The conservative strategy was associated with less use of antimicrobial agents, more appropriate antibiotic courses, and lower mortality rates. Likewise, randomized trials have reported that outcomes are similar for patients with suspected pneumonia regardless of whether they are treated as soon as pneumonia is suspected or if treatment is withheld until bronchoscopic gram stain or cultures turn positive.13,14 The findings by Jones and colleagues6 are also concordant with pilot studies suggesting that rapid discontinuation of vancomycin driven by negative MRSA polymerase chain reaction results on nasal swabs or respiratory specimens may be associated with lower mortality rates and shorter hospitalizations.15,16

All told, pneumonia is frequently overdiagnosed, MRSA and Pseudomonas are very rare in community-onset pneumonia, empirical coverage with broad-spectrum agents may be associated with higher mortality rates, and there is often no harm in deferring treatment of clinically stable patients until diagnostic microbiology is available. The messages are clear: empirical coverage with broad-spectrum agents is not indicated in most patients being treated for pneumonia, and if the diagnosis of pneumonia is uncertain, there is no harm and likely some benefit in taking some time to acquire more diagnostic clarity before treating (such as further imaging, laboratory testing, treating concurrent conditions, and/or observation), so long as the patient is clinically stable.

Back to top
Article Information

Corresponding Author: Michael Klompas, MD, MPH, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Ste 401 East, Boston, MA 02215, mklompas@bwh.harvard.edu

Published Online: February 17, 2020. doi:10.1001/jamainternmed.2019.7251

Conflict of Interest Disclosures: Dr Klompas reported receiving grant funding from the Centers for Disease Control and Prevention and the Massachusetts Department of Public Health, and royalty payments from UpToDate for articles on hospital-acquired pneumonia.

References
1.
Claessens  YE, Debray  MP, Tubach  F,  et al.  Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia.  Am J Respir Crit Care Med. 2015;192(8):974-982. doi:10.1164/rccm.201501-0017OCGoogle ScholarCrossref
2.
Daniel  P, Bewick  T, Welham  S, McKeever  TM, Lim  WS; British Thoracic Society.  Adults miscoded and misdiagnosed as having pneumonia: results from the British Thoracic Society pneumonia audit.  Thorax. 2017;72(4):376-379. doi:10.1136/thoraxjnl-2016-209405Google ScholarCrossref
3.
American Thoracic Society and Infectious Diseases Society of America.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;171(4):388-416.Google ScholarCrossref
4.
Jones  BE, Jones  MM, Huttner  B,  et al.  Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010.  Clin Infect Dis. 2015;61(9):1403-1410. doi:10.1093/cid/civ629Google ScholarCrossref
5.
Jones  M, Jernigan  JA, Evans  ME, Roselle  GA, Hatfield  KM, Samore  MH.  Vital signs: trends in Staphylococcus aureus infections in Veterans Affairs medical centers—United States, 2005-2017.  MMWR Morb Mortal Wkly Rep. 2019;68(9):220-224. doi:10.15585/mmwr.mm6809e2Google ScholarCrossref
6.
Jones  BE, Ying  J, Stevens  V,  et al.  Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia  [published online February 17, 2020].  JAMA Intern Med. doi:10.1001/jamainternmed.2019.7495Google Scholar
7.
Wunderink  RG, Niederman  MS, Kollef  MH,  et al.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.  Clin Infect Dis. 2012;54(5):621-629. doi:10.1093/cid/cir895Google ScholarCrossref
8.
Paul  M, Bishara  J, Yahav  D,  et al.  Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus: randomised controlled trial.  BMJ. 2015;350:h2219. doi:10.1136/bmj.h2219Google ScholarCrossref
9.
Webb  BJ, Sorensen  J, Jephson  A, Mecham  I, Dean  NC.  Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study.  Eur Respir J. 2019;54(1):pi:1900057. doi:10.1183/13993003.00057-2019Google Scholar
10.
Attridge  RT, Frei  CR, Restrepo  MI,  et al.  Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.  Eur Respir J. 2011;38(4):878-887. doi:10.1183/09031936.00141110Google ScholarCrossref
11.
Kett  DH, Cano  E, Quartin  AA,  et al.  Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study.  Lancet Infect Dis. 2011;11(3):181-189. doi:10.1016/S1473-3099(10)70314-5Google ScholarCrossref
12.
Hranjec  T, Rosenberger  LH, Swenson  B,  et al.  Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit–acquired infection: a quasi-experimental, before and after observational cohort study.  Lancet Infect Dis. 2012;12(10):774-780. doi:10.1016/S1473-3099(12)70151-2Google ScholarCrossref
13.
Fagon  JY, Chastre  J, Wolff  M,  et al.  Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial.  Ann Intern Med. 2000;132(8):621-630. doi:10.7326/0003-4819-132-8-200004180-00004Google ScholarCrossref
14.
Baker  AM, Meredith  JW, Chang  M, Dunagan  D, Smith  A, Haponik  E.  Bronchoscopically guided management of ventilator-associated pneumonia in trauma patients.  J Bronchol. 2003;10:7-16. doi:10.1097/00128594-200301000-00003Google ScholarCrossref
15.
Paonessa  JR, Shah  RD, Pickens  CI,  et al.  Rapid detection of methicillin-resistant Staphylococcus aureus in BAL: a pilot randomized controlled trial.  Chest. 2019;155(5):999-1007. doi:10.1016/j.chest.2019.02.007Google ScholarCrossref
16.
Baby  N, Faust  AC, Smith  T, Sheperd  LA, Knoll  L, Goodman  EL.  Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia.  Antimicrob Agents Chemother. 2017;61(4):e02432-e02416. doi:10.1128/AAC.02432-16Google ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    SEP-1 bundle drive antibiotic overuse
    Amit Desai, HOSPITALIST | Non for profit Hospital
    Wonderful editorial on harm's of broad spectrum coverage of patients with pneumonia. Unfortunately, a driving force behind antibiotic prescribing not mentioned in the article is SEP-1 mandate that pushes for a time sensitive bundled care for severe sepsis. Despite lack of evidence of any such bundle to improve outcome such protocol based care is not only pushed for by CMS but now has become a corporate mandate with incredible amount of investment of dollars to set up an infrastructure that forces compliance. There is a financial penalty for physicians in many organizations for not diagnosing patients to be sick from severe sepsis. Unfortunately, physicians who overdiagnose severe sepsis most commonly from pneumonia or UTI are financially rewarded putting immense pressure on physicians who have reluctance to comply and would prefer nuance. Many such patients who get exposed to broad spectrum antibiotics for pneumonia are often frail and should be receiving high quality and compassionate end of life care. Unfortunately such discussions are often shelved to make room for compliance with bundles with patient's needlessly dying in an ICU.
    CONFLICT OF INTEREST: None Reported
    READ MORE
    ×